CD276 (B7-H3) Monoclonal Antibody (MIH35), Functional Grade, eBioscience™, Invitrogen™

Description

Description: This monoclonal antibody reacts with mouse and human CD276 (also known as B7-H3), a type I transmembrane protein belonging to the B7 family of costimulatory proteins. B7-H3 is expressed weakly on activated lymphocytes, macrophages, dendritic cells, nasal and airway epithelial cells, osteoblasts, and some tumor cell lines. A soluble form of B7-H3 is also secreted by monocytes, dendritic cells, and activated T cells. Although the biological role of this molecule remains controversial, recent studies have identified B7-H3 as the ligand for TREM-like 2 (TLT-2). Applications Reported: This MIH35 antibody has been reported for use in functional assays and flow cytometric analysis. Applications Tested: This MIH35 antibody has been tested for blocking activity in mouse, as well as by flow cytometric analysis on transfected cell lines. This can be used at 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Endotoxin: Less than 0.001 ng/ug antibody as determined by the LAL assay. Storage and handling: Use in a sterile environment. Filtration: 0.2 μm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE.

CD276 is a member of the B7 family of co-stimulatory molecules also known as B7-H3. CD276 is a type I transmembrane protein that induces the proliferation of CD4+ and CD8+ T cells, enhances the generation of cytotoxic T cells and selectively stimulates the production of interferon gamma. Expression of CD276 can be induced on dendritic cells and monocytes by inflammatory cytokines, and is also widely expressed in peripheral tissues including the heart, kidney, testis and colon. In humans, CD276 exists as two isoforms which result from gene duplication and differential splicing. CD276 is reported to have therapeutic potential for the regulation of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy.